Vitamin D Inhibits Prostate Cancer Growth In Animal, Find University Of Pittsburgh Cancer Institute Researchers

April 14, 1997

San Diego, April 10 -- Vitamin D significantly inhibits highly metastatic, or widespread, prostate cancer in animals, suggesting that it has important potential for treating men with similar advanced disease. "This is the first evidence that vitamin D can effectively treat an animal with advanced prostate cancer that spreads to the bone, similar to what happens in men affected with this disease," said Ben Light, M.D., a researcher with the UPCI's Experimental Therapeutics Program who presented these findings April 14 at the annual meeting of the American Association for Cancer Research.

In their study, the UPCI research team implanted highly metastatic prostate tumors into rats and treated them with vitamin D (1,25-dihydroxycholecalciferol). After 3 weeks of therapy, tumors in treated rats were 88 percent smaller than those in control rats which received tumors but were not treated. In addition, the treated rats had 75 percent fewer lung metastases, and these metastases were 85 percent smaller than those seen in untreated controls.

UPCI scientists were the first to describe vitamin D's anti-cancer effects in this prostate model. Past epidemiologic studies by UPCI investigators and others have shown that old age, black race, and residence in northern latitudes -- known risk factors for prostate cancer -- all correlate with low blood levels of vitamin D. Recently, they have shown that vitamin D may be involved in the growth and differentiation of the normal prostate. Vitamin D binds to cancer cells and triggers either cancer cell death or the transformation of cancer cells into more benign, less malignant cells.

UPCI clinical investigators are currently incorporating vitamin D in early clinical studies for advanced prostate cancer as well as other tumors.

Other investigators involved in the research include Candace Johnson, Ph.D., Robert Getzenberg, Ph.D., and Donald Trump, M.D.

University of Pittsburgh Medical Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to